{"schema_version":"secwatch.filing_event.v1","accession":"0000883984-23-000007","form_type":"8-K","ticker":"ICUI","cik":"0000883984","company_name":"ICU MEDICAL INC/DE","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.382888+00:00","generated_at":"2026-06-19T00:16:46.963475+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ICU Medical Q4 2022 revenue $578M, GAAP net loss $15.5M, provides FY23 guidance","bullets":["Revenue $578.0M vs $340.5M YoY; GAAP net loss $(15.5)M ($(0.65)/diluted) vs net income $19.9M ($0.91) in Q4 2021.","Adjusted diluted EPS $1.60 vs $1.82 YoY; adjusted EBITDA $96.4M vs $64.2M.","GAAP gross margin 30% vs 37% YoY; gross profit $174.9M vs $127.5M.","Fiscal year 2023 guidance announced but specific numbers not included in the excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0000883984-23-000007","json":"https://secwatch.observer/filing/0000883984-23-000007.json","markdown":"https://secwatch.observer/filing/0000883984-23-000007.md","text":"https://secwatch.observer/filing/0000883984-23-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/883984/000088398423000007/0000883984-23-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/883984/000088398423000007/icui-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T00:16:46.963475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e262b13f9589bdb20cf6c64d9eda3e81bd530a4d","claim":"ICU MEDICAL INC/DE reported the fourth quarter of 2022 results: revenue $578.0 million, net income $(15.5) million, EPS $(0.65) per diluted share.","evidence_excerpt":"Fourth quarter 2022 revenue was $578.0 million, compared to $340.5 million in the same period last year. GAAP gross profit for the fourth quarter of 2022 was $174.9 million, as compared to $127.5 million in the same period last year. GAAP gross margin for the fourth quarter of 2022 was 30%, as compared to 37% in the same period last year. GAAP net loss for the fourth quarter of 2022 was $(15.5) million, or $(0.65) per diluted share, as compared to GAAP net income of $19.9 million, or $0.91 per diluted share, for the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/883984/000088398423000007/0000883984-23-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$578.0 million"},{"label":"Net income","value":"$(15.5) million"},{"label":"EPS","value":"$(0.65) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}